ES2191170T3 - Nuevos (-)-enantiomeros de derivados de cis-3,4-cromano utiles en la prevencion y tratamiento de sindromes o enfermedades relacionadas con el estrogeno. - Google Patents

Nuevos (-)-enantiomeros de derivados de cis-3,4-cromano utiles en la prevencion y tratamiento de sindromes o enfermedades relacionadas con el estrogeno.

Info

Publication number
ES2191170T3
ES2191170T3 ES97909215T ES97909215T ES2191170T3 ES 2191170 T3 ES2191170 T3 ES 2191170T3 ES 97909215 T ES97909215 T ES 97909215T ES 97909215 T ES97909215 T ES 97909215T ES 2191170 T3 ES2191170 T3 ES 2191170T3
Authority
ES
Spain
Prior art keywords
prevention
treatment
new
strogen
syndromes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97909215T
Other languages
English (en)
Inventor
Paul Jacobsen
Svend Treppendahl
Paul Stanley Bury
Anders Kanstrup
Lise Brown Christiansen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Application granted granted Critical
Publication of ES2191170T3 publication Critical patent/ES2191170T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/74—Benzo[b]pyrans, hydrogenated in the carbocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A UNOS COMPUESTOS TERAPEUTICAMENTE ACTIVOS REPRESENTADOS POR LA FORMULA (I), A UN PROCEDIMIENTO QUE SIRVE PARA PREPARARLOS Y A UNAS COMPOSICIONES FARMACEUTICAS QUE CONTIENEN ESTOS COMPUESTOS. ESTOS NUEVOS COMPUESTOS SON UTILES PARA LA PREVENCION Y EL TRATAMIENTO DE ENFERMEDADES O DE SINDROMES ASOCIADOS A LOS ESTROGENOS.
ES97909215T 1996-10-28 1997-10-28 Nuevos (-)-enantiomeros de derivados de cis-3,4-cromano utiles en la prevencion y tratamiento de sindromes o enfermedades relacionadas con el estrogeno. Expired - Lifetime ES2191170T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK120396 1996-10-28

Publications (1)

Publication Number Publication Date
ES2191170T3 true ES2191170T3 (es) 2003-09-01

Family

ID=8102141

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97909215T Expired - Lifetime ES2191170T3 (es) 1996-10-28 1997-10-28 Nuevos (-)-enantiomeros de derivados de cis-3,4-cromano utiles en la prevencion y tratamiento de sindromes o enfermedades relacionadas con el estrogeno.

Country Status (12)

Country Link
EP (1) EP0937057B1 (es)
JP (1) JP2001502704A (es)
AT (1) ATE231141T1 (es)
AU (1) AU4699897A (es)
CA (1) CA2270111A1 (es)
DE (1) DE69718500T2 (es)
DK (1) DK0937057T3 (es)
ES (1) ES2191170T3 (es)
IL (1) IL129625A0 (es)
NO (1) NO992007L (es)
WO (1) WO1998018771A1 (es)
ZA (1) ZA979645B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1140889B1 (en) * 1998-12-30 2003-08-27 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
US7214706B2 (en) 2000-03-01 2007-05-08 Akzo Nobel N.V. Chroman derivatives as estrogenic compounds
EP1794141B1 (en) 2004-09-21 2011-11-09 Marshall Edwards, Inc. Substituted chroman derivatives, medicaments and use in therapy
US8080675B2 (en) 2004-09-21 2011-12-20 Marshall Edwards, Inc. Chroman derivatives, medicaments and use in therapy
JP6013349B2 (ja) 2010-11-01 2016-10-25 メイ ファーマ, インク.Mei Pharma, Inc. 癌の処置のためのイソフラボノイド化合物および方法
WO2015117202A1 (en) 2014-02-07 2015-08-13 Novogen Limited Functionalised benzopyran compounds and use thereof
CN116139125A (zh) 2015-02-02 2023-05-23 梅制药公司 联合治疗

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3340276A (en) * 1964-04-01 1967-09-05 Ciba Geigy Corp 3, 4-diphenyl-chromans
DE1543749A1 (de) * 1966-02-16 1969-12-11 Merck Ag E Verfahren zur Herstellung von 3,4-cis-4-Aryl-isoflavanen
US5280040A (en) * 1993-03-11 1994-01-18 Zymogenetics, Inc. Methods for reducing bone loss using centchroman derivatives
HUP9702244A3 (en) * 1995-01-13 1999-12-28 Novo Nordisk As Use of 3,4-diphenyl chromans for manufacture of a pharmaceutical composition for treatment or prophylaxis of gynaecological disorders

Also Published As

Publication number Publication date
EP0937057B1 (en) 2003-01-15
DE69718500T2 (de) 2003-11-27
ZA979645B (en) 1998-04-28
NO992007L (no) 1999-06-25
WO1998018771A1 (en) 1998-05-07
NO992007D0 (no) 1999-04-27
EP0937057A1 (en) 1999-08-25
DE69718500D1 (de) 2003-02-20
JP2001502704A (ja) 2001-02-27
AU4699897A (en) 1998-05-22
CA2270111A1 (en) 1998-05-07
DK0937057T3 (da) 2003-05-05
ATE231141T1 (de) 2003-02-15
IL129625A0 (en) 2000-02-29

Similar Documents

Publication Publication Date Title
CR20120007A (es) 2-indolinonas sustituidas con pirrolos inhibidores de proteinquinasas (divisional exp. 6728)
SV1998000029A (es) Compuestos de pirazina ref. pg3186
ES2081187T3 (es) Nuevas naftil-alquil-aminas, su procedimiento de preparacion y composiciones farmaceuticas que las contienen.
ES2062943B1 (es) Nuevos derivados de la (2-metil-3-piridil) cianometilpiperazinas.
MX9404749A (es) Heterociclos de fenilo como inhibidores de cox-2.
PA8442001A1 (es) Derivados de pirimidina biciclica condensada
ECSP941122A (es) Derivados de 5-arilindoles
UY26839A1 (es) Productos de derivados de la 4 - fenil - piridina
CO4290353A1 (es) Agonistas de estrogeno
PA8452001A1 (es) Derivados de macrolidos c-4" sustituidos
ES2065701T3 (es) Furoato de mometasona monohidrato, procedimiento para fabricar el mismo y composiciones farmaceuticas.
ES2163407T3 (es) Derivados piperidinilos tiaciclicos.
ES2188908T3 (es) Derivados de cis-3,4-cromano utiles para la prevencion o tratamiento de sindromes relacionados con el estrogenos.
MX9301197A (es) Derivados de indol.
PA8457001A1 (es) Derivados del 2-(4-aril o heteroaril-piperazin-i-ilmetil)-1h-indol
MX9306311A (es) Compuestos antagonistas del receptor de 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
SE9801494D0 (sv) Novel use
PT96030A (pt) Processo para a preparacao de aminocarbonilcarbamatos relacionados com fisoestigmina e de composicoes farmaceuticas que os contem
ES2148458T3 (es) Derivados de fenil-4-tiazoles sustituidos, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
ES2191170T3 (es) Nuevos (-)-enantiomeros de derivados de cis-3,4-cromano utiles en la prevencion y tratamiento de sindromes o enfermedades relacionadas con el estrogeno.
ES2123499T3 (es) Metodos y composiciones para tratamiento de infecciones virales.
MX9305510A (es) Compuestos para el tratamiento o profilaxis de desordenes gastrointestinales, cardiovasculares y del sistema nervioso central, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
ES2116612T3 (es) Nuevas bis-naftalimidas para el tratamiento del cancer.
MX9301112A (es) Derivados de indol.
SV1998000013A (es) Derivados de 5-aroilnaftaleno ref.-ran 4070\115